Literature DB >> 8812533

Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases.

F di Re1, G Baiocchi, R Fontanelli, G Grosso, L Cobellis, F Raspagliesi, E di Re.   

Abstract

A retrospective study of 488 patients with untreated advanced ovarian cancer is presented. Systematic pelvic and paraaortic lymphadenectomy was performed in 248 cases (50.8%). Selective sampling and node biopsy was performed in 33 (6.7%) and 47 (9.6%) patients, respectively. Node metastases were found in 194 of 328 patients (59.1%). The incidence of metastatic nodes significantly increased with more advanced stages, with serous histology, and with a greater amount of residual tumor. Node status appeared to be related to pathology findings at second-look. A complete pathologic response was documented in 26 of 31 (83.8%) patients with negative nodes and in 38 of 59 (64.6%) with positive nodes at first surgery. Patients with negative nodes survived significantly longer (5-year survival, 46%; median, 60 months) than those who had node metastases (5-year survival, 25%; median, 36 months). Using multivariate analysis, lymph node status, together with the stage of disease and residual tumor, still had a significant impact on 5-year survival. Moreover, among patients with optimal cytoreduction, 5-year survival was 46% (median, 56 months) and 30% (median, 41 months) for patients who did and did not undergo lymphadenectomy, respectively (P = 0.05). Likewise, when suboptimal cytoreduction was considered, a median 5-year survival of 24 months was obtained in patients who underwent lymphadenectomy compared with 14 months in patients who did not (P < 0.005).

Entities:  

Mesh:

Year:  1996        PMID: 8812533     DOI: 10.1006/gyno.1996.0249

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

Review 1.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Prognosis and conditional disease-free survival among patients with ovarian cancer.

Authors:  Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

3.  Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Authors:  Cornelia Bachmann; Robert Bachmann; Bernhard Kraemer; Sara Yvonne Brucker; Anette Staebler; Falko Fend; Ralf Rothmund; Diethelm Wallwiener
Journal:  Mol Clin Oncol       Date:  2016-08-05

4.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

5.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

Review 6.  Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Authors:  Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-09-26

7.  Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.

Authors:  Shanshan Yang; Huiyan Li; Yunduo Liu; Xiaoming Ning; Fanling Meng; Min Xiao; Deying Wang; Ge Lou; Yunyan Zhang
Journal:  Med Oncol       Date:  2012-12-18       Impact factor: 3.064

Review 8.  [The role of radical lymphadenectomy. Experiences from the AGO Ovarian Cancer Study Group].

Authors:  P Wimberger; R Kimmig
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

9.  Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute.

Authors:  Anne Marszalek; Séverine Alran; Suzy Scholl; Virginie Fourchotte; Corinne Plancher; Christophe Rosty; Jean Philippe Meyniel; Vincent De Margerie; Thierry Dorval; Anne De La Rochefordière; Paul Cottu; Peter Petrow; Xavier Sastre-Garrau; Rémy Jacques Salmon
Journal:  Int J Surg Oncol       Date:  2010-07-25

10.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.